Search Results - "Kurata, Yasuko"

Alternate-day Treatment with Crizotinib for Drug-induced Esophagitis and Liver Damage in a Patient with EML4-ALK Fusion Gene-positive Lung Adenocarcinoma by Tsukita, Yoko, Fukuhara, Tatsuro, Kobayashi, Maki, Morita, Mami, Suzuki, Aya, Watanabe, Kana, Noguchi, Tetsuya, Kurata, Yasuko, Suno, Manabu, Maemondo, Makoto

“…A 44-year-old woman who was diagnosed with anaplastic lymphoma kinase-positive lung adenocarcinoma developed brain metastases, multiple spinal metastases and…”
Get full text

Efficacy of Metformin in Patients With Breast Cancer Receiving Chemotherapy or Endocrine Therapy: Systematic Review and Meta-analysis by Morio, Kayoko, Kurata, Yasuko, Kawaguchi-Sakita, Nobuko, Shiroshita, Akihiro, Kataoka, Yuki

“…Background Previous studies have suggested that metformin might improve survival outcomes in patients with breast cancer. However, findings on the efficacy of…”
Get full text

Ganglioside inserted into PEGylated liposome attenuates anti-PEG immunity by Mima, Yu, Abu Lila, Amr S., Shimizu, Taro, Ukawa, Masami, Ando, Hidenori, Kurata, Yasuko, Ishida, Tatsuhiro

“…Despite the clinical introduction of a vast number of polyethylene glycol (PEG)-conjugated therapeutics, conjugated PEG is also known for an unfortunate…”
Get full text

Corrigendum to "Quality of clinical practice guidelines in Japan remains low: a cross-sectional meta-epidemiological study" [Journal of Clinical Epidemiology 138 (2021) 10550] by Kataoka, Yuki, Anan, Keisuke, Taito, Shunsuke, Tsujimoto, Yasushi, Kurata, Yasuko, Wada, Yoshitaka, Maruta, Masaki, Kanaoka, Koshiro, Oide, Shiho, Takahashi, Sei, Nango, Eishu

Get full text

Quality of clinical practice guidelines in Japan remains low: A cross-sectional meta-epidemiological study by Kataoka, Yuki, Anan, Keisuke, Taito, Shunsuke, Tsujimoto, Yasushi, Kurata, Yasuko, Wada, Yoshitaka, Maruta, Masaki, Kanaoka, Koshiro, Oide, Shiho, Takahashi, Sei, Nango, Eishu

“…We aimed to evaluate the characteristics, quality, and related factors of the Japanese Clinical Practice Guidelines (CPGs) published in recent years. In this…”
Get full text

Abstract 4667: pCR induced by triplet therapy with low-dose afatinib, cetuximab and bevcizumab in lung cancer cells harboring EGFR T790M by Ohashi, Kadoaki, Kudo, Kenichiro, Ichihara, Eiki, Kayatani, Hiroe, Higo, Hisao, Kato, Yuka, Kurata, Yasuko, Minami, Daisuke, Ninomiya, Takashi, Kubo, Toshio, Hotta, Katsuyuki, Tanimoto, Mitsune, Kiura, Katsuyuki

“…Abstract Background. EGFR T790M plays a major role on the resistance for 1st or 2nd-generation EGFR-TKIs (e.g. erlotinib, afatinib) in lung tumors with…”
Get full text

Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo by Kudo, Kenichiro, Ohashi, Kadoaki, Makimoto, Go, Higo, Hisao, Kato, Yuka, Kayatani, Hiroe, Kurata, Yasuko, Takami, Yoichiro, Minami, Daisuke, Ninomiya, Takashi, Kubo, Toshio, Ichihara, Eiki, Sato, Akiko, Hotta, Katsuyuki, Yoshino, Tadashi, Tanimoto, Mitsune, Kiura, Katsuyuki

“…Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR‐mutant lung cancers; however, resistance…”
Get full text

Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia by Sato, Shiho, Zamami, Yoshito, Imai, Toru, Tanaka, Satoshi, Koyama, Toshihiro, Niimura, Takahiro, Chuma, Masayuki, Koga, Tadashi, Takechi, Kenshi, Kurata, Yasuko, Kondo, Yutaka, Izawa-Ishizawa, Yuki, Sendo, Toshiaki, Nakura, Hironori, Ishizawa, Keisuke

“…Amiodarone (AMD) and nifekalant (NIF) are used in the treatment of ventricular fibrillation or tachycardia; however, only few studies have been conducted on…”
Get full text

Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer by Kurata, Yasuko, Miyauchi, Narumi, Suno, Manabu, Ito, Takahiro, Sendo, Toshiaki, Kiura, Katsuyuki

“…Crizotinib, an ATP-competitive receptor tyrosine kinase inhibitor of both anaplastic lymphoma kinase (ALK) and the hepatocyte growth factor receptor, commonly…”
Get full text